What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)?
Bristol-Myers Squibb Company (NYSE:BMY) is one of the best immunotherapy stocks to buy according to hedge funds. Bristol-Myers Squibb Company (NYSE:BMY) announced on February 12 plans to become an inaugural partner to Life Science Cares in support of its national campaign in fighting food insecurity. Management reported that the Food is Health: Nourishing Communities, Advancing Health initiative, led by Life Science Cares, aims to invest $30 million and mobilize 30,000 volunteer hours by 2030 to deliver a measurable and lasting impact for communities across the nation.
In another development, Bernstein reiterated its Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) on February 10 and set a price target of $58.00. Bristol-Myers Squibb Company (NYSE:BMY) also received a rating update from Morgan Stanley on February 6, which lifted the price target on the stock to $40 from $37 while keeping an Underweight rating on the shares. The firm told investors in a research note that while the 2026 revenue and EPS guidance exceeded consensus, it was driven by a higher-than-expected Eliquis guide.
The rating updates came after Bristol-Myers Squibb Company (NYSE:BMY) reported fiscal Q4 and full-year financial results for 2025, reporting a 1% growth in fiscal Q4 revenue to $12.5 billion, with growth portfolio revenue rising 16% to $7.4 billion. Full-year revenues reached $48.2 billion, and growth portfolio revenues increased 17% to $26.4 billion.
Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including oncology, cardiovascular, immunology, and neuroscience.
While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
How Ethereum Could Stay Secure Even If Today’s Online Locks Stop Working
Cardano Price Prediction: Can ADA Defend $0.22 as Hoskinson Builds a New Programming Language?
VIPAI Asset Sell-Off and Selective Rotation in Crypto
1. Technology stocks fell sharply as investor interest shifted toward energy and selected defensive assets. From October 10 to 16, the Nasdaq 100 declined 5.49% and the S&P 500 fell 1.95%, while the Dow gained 0.67% and WTI crude rose 10.41%. BTC, ETH, and SOL declined 1.27%, 2.65%, and 4.44%, respectively. This week's technology earnings will be an important test of whether revenue growth, margins, and cash flow can justify current valuations. Better-than-expected results could help stabilize markets in the near term. 2. Crypto continues to see pockets of strong activity, but a broad-based altcoin season has yet to materialize. CoinMarketCap's (CMC) Altcoin Season Index stood at 54 as of the October 18 UTC daily observation, below the altcoin-season threshold of 75, while BTC dominance rose to 60.08%. Our proxy leverage ratio fluctuated between 4.00 and 4.07 during the week, showing no sustained increase and suggesting limited appetite for additional leverage. Meanwhile, as major exchanges expand access to traditional financial assets, the recent sell-off in AI-related equities could attract short-term speculative capital away from crypto. Such capital rotation could make it more difficult for a new altcoin season to take hold. 3. Papertrade's loss-to-mine model has generated significant interest across the crypto community. The protocol combines high-leverage derivatives trading with zero slippage and a mechanism that rewards trading losses with PAPER tokens. Across the eight complete UTC days from October 10 to 17, cumulative reported revenue reached approximately $56.08 million, including $51.90 million distributed to token holders. With growing participation from key opinion leaders (KOLs), Papertrade has reportedly ranked among the top three platforms by profitability in the broader market recently. Assets to watch: BTC, ETH, SOL, ARB, OP, SKHYNIX, SKHY, META, TSLA, LRCX, and SPCX. Key research priorities this week: Cash flow performance in technology earnings; the relative discount and holding costs of the two SK Hynix contracts; and U.S. initial jobless claims and PMI data. Weekly market data cover the period through October 16, while research information was verified through October 18. Observation periods are specified separately for each chart.
Why Bernstein Thinks the AI Stock Sell-Off Could Help Small Caps
Crypto prices
More
